Optibiotix Health Share Discussion Threads

[pglancy] 17/11/2017 12:13

surely this pull back has something to do with investors concerned there is no update on lpgos production. Wasnt is suppose to start this month. Like slombiome should have been in production before the end of this year and now we are looking into 2018. We should be kept informed surely.

[parob] 17/11/2017 11:26

Guys,Quick one as crazy at work today. I've just received cholesterol results having taken Lactobact LDL-Control since July so about 4 months. Unlike Nick and Adnan I have continued to take statins (been on them about 2 years)I am super impressed by further reductions in both total and LDL cholesterol! Will share results this evening or tomorrow when I'm at home and can check pre/post statin dates/cholesterol results.Just wanted to share the good news!

[mr dexy] 17/11/2017 10:40

Interesting Dev... veeery interesting

;)

Regards & best wishes to all


Mr D

[devonlad] 17/11/2017 09:43

No worries Aspex, they share many similarities as business models and both are pretty much at exactly the same stage of development, VRS and OPTI are my top two holdings.

[aspex] 17/11/2017 09:07

Hi Devonlad,Funnily enough I have just been doing that for the last few minutes. I may have to have a dabble.

[devonlad] 17/11/2017 08:52

OT but I hold both shares and they have very similar attributes. Ground breaking technology like OPTI and at the point of commercialisation, take a peak at VRS, sorry for being off topic, no advice intended, just worth researching.

[rafboy] 17/11/2017 08:43

Yes, I agree that we have a first class management team here at OPTI. It is that combination of science know how and integrity that is often lacking in some Aim companies but not with SOH and his team.

[fathenry] 17/11/2017 08:42

slartyfarty , whileye bullyboy away, seen trak today, upagin, youtosspot

[owenmo] 17/11/2017 08:41

Typo: “the integrity of the team and of the model”. Owenmo

[owenmo] 17/11/2017 08:36

We’ll always have people who see the world differently, that’s a given; it’s what makes the market. Whatever of the naysayers and doubting Thomass, in the event this business models brings home the bacon, as many of us confidently expect it will, in hindsight will AIM ever have presented a more glaring opportunity, a more skewed risk/return model than Opti - weighing up all the factors? A no-brained as some of us see it. If we’re on the money, we’ll have taken least amount of risk for optimum return, that’s for certain. As i’d have opined before, and as most of us agree unequivocally, it’s the integrity of the team and if the model that sustains our faith in a long-drawn-out period of share price stagnation, good news notwithstanding. 2018 looms.

[aspex] 17/11/2017 08:25

Taken on another 16000 and more than happy to absorb any small short term risk.

[slartybartfaster] 17/11/2017 00:09

your a card elrico

[2350220] 16/11/2017 23:05

Thanks for that in-depth research Elrico.
John

[elrico] 16/11/2017 22:26

Primal - Slarty is correct, as he so eloquently said, there is no point watching traders being mugged, even if they do manage to squeeze a few rounds out for the weekend. SOH has made the point about II wanting it via a placing, thankfully, he is standing firm. They will have to buy via the market - how refreshing to have a CEO that don't buckle under cunningness of the II fund managers.

[loungeact] 16/11/2017 22:21

Great work Primal.

[monkeywench1] 16/11/2017 22:10

Mmmmm lots of words.

[elrico] 16/11/2017 21:51

Global Human Microbiome Market Outlook 2017 Growth, Trends and Forecasts 2022 Ritter Pharmaceuticals, E. I. du Pont de Nemours and Company, Optibiotix Health Plc, Vedanta Biosciences, MicroBiome Therapeutics.

It's part of a premium report which singles out companies expected to have an impact on the human microbiome.

Global Human Microbiome Market 2017 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Combining the data integration and analysis capabilities with the relevant findings, the report has predicted strong future growth of the Human Microbiome market in all its geographical and product segments.

What’s more, the Human Microbiome industry development trends and marketing channels are analyzed. The industry analysis have also been done to examine the impact of various factors and understand the overall attractiveness of the industry.

Overview of Human Microbiome market:
The report begins with a market overview and moves on to cover the growth prospects of the Human Microbiome market. A detailed segmentation analysis of the Human Microbiome market is available in the report. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals.

This report also presents product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals. In the end, the report includes Human Microbiome new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis.

Questions are answered in Human Microbiome Market report:
-Which application segments will perform well in the Human Microbiome over the next few years?
-Which are the markets where companies should establish a presence?
-What are the restraints that will threaten growth rate?
-What are the forecasted growth rates for the Human Microbiome market as a whole and for each segment within it?

All of these questions are answered using industry-leading techniques and tools as well as a vast amount of qualitative research.

Manufacturers Analysis and Top Sellers of Global Human Microbiome Market 2017 :

ViThera Pharmaceuticals,
Metabiomics,
ActoGeniX,
Ritter Pharmaceuticals,
E. I. du Pont de Nemours and Company,
Optibiotix Health Plc,
Vedanta Biosciences,
MicroBiome Therapeutics

Browse Complete report with TOC @ www.marketresearchstore.com/report/human-microbiome-global-market-outlook-84659

[primal123] 16/11/2017 19:50

No problem, yes it's only a matter of time, we can all see what SOH is doing and we have deals with major corporates!

[slartybartfaster] 16/11/2017 19:31

Well done primal. Never concerned with trades, why worry when you cant control them. The sooner the ii have mugged the blind and the stupid the better of us lth.

Oh no another tw troll holding up a bank robber with tw grudge as a moral icon.

[nicktopten] 16/11/2017 19:13

well done Primal !... Its only a matter of time (FFS!).... all looking good. :)

[primal123] 16/11/2017 18:38

I was asking SOH about the trading range we are in as people are selling in 70s and buying in 60s and if this worries him, his comments were:

“There is trading range which PI’s and market makers are exploiting to their short term benefit which invariably happens when a company has a high number of retail investors which comes with an associated share volatility. We are gradually bringing in more institutional holdings but this is a protracted process when there is no plans for a fund raise.

My focus is on building the company from a £55m-£60m business to £200m company and most investors see the opportunity and strong deal flow, and the development of the company from an early stage R&D house to one building up commercial traction across a wide number of areas. I am sure most investors recognise that it is highly unusual to attract corporates such as Tata and DSM at such an early stage in a companies development. The day to day volatility does not concern me. “

I also asked him about the comments from someone at CII, (game changer comment) which Parob posted the other day, he said:

“If you can share Linked in comments like this on the blogs it will all help investors understand this is part of a process of building up the innovative science with world experts, proving the science in humans studies, and developing partnerships across the world with innovative companies who see the game changing nature of our technology in their products. And remember we still have a 42% share in SBTX, SweetBiotix, microbial modulation, and Psychobiotics to come.”

Obviously he thinks that some are still not understanding what they are doing.

[parob] 16/11/2017 16:44

OPTIBIOTIX HEALTH on LinkedIn:

We are so proud and excited to be a finalist in the Food Matters Live Awards for Best Functional Ingredient for Health & Wellbeing! Only a week to go...

[city chappy] 16/11/2017 15:32

Back on the rise and gorwing revenues.

[onedayrodders] 16/11/2017 15:30

Nice to see recent uptrend still intact on chart